Foghorn Therapeutics Inc.
FHTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001822462
No open-market purchases or sales by Foghorn Therapeutics Inc. insiders were filed in the last 90 days; 102 institutions reported holding it in 13F filings for Q2 2026, worth $219.2M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Foghorn Therapeutics Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Of which not filed for Q4 2024 | Q4 2024 | Change |
|---|---|---|---|---|
| Holders | 79 | 1 | 87 | +9 |
| Shares | 40.0M | 2.30M | 40.3M | +2.55M (+6.8%) |
| Value | $372.4M | $21.4M | $190.0M | −$161.0M (−45.9%) |
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Foghorn Therapeutics Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Raymond James Financial Inc | 2,029,383 | $9.58M | 0.00% |
| Wingate Wealth Advisors, Inc. | 28,471 | $134.4K | 0.13% |
| Los Angeles Capital Management LLC | 15,851 | $74.8K | 0.00% |
| BNP Paribas Arbitrage, SA | 12,946 | $61.1K | 0.00% |
| China Universal Asset Management Co., Ltd. | 11,788 | $55.6K | 0.01% |
| Cubist Systematic Strategies, LLC | 10,895 | $51.4K | 0.00% |
| Lazard Asset Management LLC | 10,582 | $49.0K | 0.00% |
| Evelyn Partners Asset Management Ltd | 7,100 | $33.5K | 0.01% |
| Police & Firemen's Retirement System of New Jersey | 5,078 | $24.0K | 0.00% |
| Mirae Asset Global Investments Co., Ltd. | 1,853 | $8.93K | 0.00% |
| GF Fund Management Co. Ltd. | 1,167 | $5.51K | 0.00% |
| Simplex Trading, LLC | 680 | $3.00K | 0.00% |
| Point72 (DIFC) Ltd | 509 | $2.40K | 0.00% |
| GAMMA Investing LLC | 111 | $524 | 0.00% |
| R Squared Ltd | 30 | $142 | 0.00% |
| IFP Advisors, Inc | 2 | $9 | 0.00% |
| SBI Securities Co., Ltd. | 1 | $5 | 0.00% |
Sold out (8)
Institutions that held Foghorn Therapeutics Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Citadel Advisors LLC | 81,204 | $756.0K |
| Jane Street Group, LLC | 18,547 | $172.7K |
| MetLife Investment Management | 15,898 | $148.0K |
| Cornercap Investment Counsel Inc | 13,147 | $122.4K |
| XTX Topco Ltd | 10,900 | $101.5K |
| Zacks Investment Management | 10,300 | $95.9K |
| Catalyst Funds Management Pty Ltd | 1,000 | $9.31K |
| Capital Performance Advisors LLP | 14 | $130 |
Not filed for Q4 2024 yet (1)
Institutions that held Foghorn Therapeutics Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Raymond James & Associates | 2,297,319 | $21.4M |